JOP20140092B1 - 2-ازا باي سايكليس و استخداماتها كمعدلات لمستقبل اوريكسين - Google Patents
2-ازا باي سايكليس و استخداماتها كمعدلات لمستقبل اوريكسينInfo
- Publication number
- JOP20140092B1 JOP20140092B1 JOP/2014/0092A JOP20140092A JOP20140092B1 JO P20140092 B1 JOP20140092 B1 JO P20140092B1 JO P20140092 A JOP20140092 A JO P20140092A JO P20140092 B1 JOP20140092 B1 JO P20140092B1
- Authority
- JO
- Jordan
- Prior art keywords
- halo
- alkyl
- compounds
- azabicyclies
- substituted
- Prior art date
Links
- 108050000742 Orexin Receptor Proteins 0.000 title 1
- 102000008834 Orexin receptor Human genes 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 3
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000001425 triazolyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780378P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20140092B1 true JOP20140092B1 (ar) | 2021-08-17 |
Family
ID=50487148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2014/0092A JOP20140092B1 (ar) | 2013-03-13 | 2014-03-12 | 2-ازا باي سايكليس و استخداماتها كمعدلات لمستقبل اوريكسين |
Country Status (38)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012004753A (es) | 2009-10-23 | 2012-09-07 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina. |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| TWI621618B (zh) * | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| JP6262885B2 (ja) | 2014-03-06 | 2018-01-17 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | オレキシン受容体拮抗剤としてのピペリジン誘導体 |
| WO2016040789A1 (en) * | 2014-09-11 | 2016-03-17 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
| WO2016100157A2 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| AU2016295693B2 (en) | 2015-07-17 | 2020-05-21 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| WO2017028732A1 (zh) * | 2015-08-14 | 2017-02-23 | 上海海雁医药科技有限公司 | 食欲素受体拮抗剂化合物的晶型及其制备方法和应用 |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JP6936224B2 (ja) | 2015-11-23 | 2021-09-15 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | オクタヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用 |
| UA125873C2 (uk) | 2016-03-10 | 2022-06-29 | Янссен Фармацевтика Нв | Спосіб лікування депресії з використанням антагоністів рецептора орексин-2 |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| JP6678779B2 (ja) | 2016-06-13 | 2020-04-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒ（ｎｒ１ｈ４）調節化合物 |
| AU2017363307B2 (en) | 2016-11-22 | 2021-07-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof |
| PT4122464T (pt) | 2017-03-28 | 2024-06-27 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças do fígado |
| GB2558975B (en) * | 2017-09-01 | 2019-01-23 | Chronos Therapeutics Ltd | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists |
| JP7391012B2 (ja) | 2017-09-01 | 2023-12-04 | クロノス セラピューティクス リミテッド | オレキシン受容体拮抗薬としての置換２－アザビシクロ［３．１．１］ヘプタンおよび２－アザビシクロ［３．２．１］オクタン誘導体 |
| CA3099763A1 (en) | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| JP7642540B2 (ja) * | 2018-12-14 | 2025-03-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ－ｊｕｎ－ｎ末キナーゼのピラゾロピリジンインヒビターおよびそれらの使用 |
| CA3124422A1 (en) | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| SG11202107434PA (en) | 2019-01-15 | 2021-08-30 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CN118388473A (zh) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Fxr激动剂的固体形式 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3674793A (en) | 1967-03-29 | 1972-07-04 | Sterling Drug Inc | 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones |
| US6505492B2 (en) | 2001-04-11 | 2003-01-14 | Bethlehem Steel Corporation | Method and apparatus for forming deep-drawn articles |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| WO2004069816A1 (en) | 2003-02-07 | 2004-08-19 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
| CA2516329A1 (en) | 2003-02-21 | 2004-09-02 | Pharmacia & Upjohn Company Llc | Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them |
| BRPI0620066A2 (pt) | 2005-12-20 | 2011-11-01 | Novartis Ag | derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados |
| CA2663113A1 (en) | 2006-09-11 | 2008-03-20 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutanate receptors |
| ES2357992T3 (es) | 2006-12-01 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina. |
| AR064561A1 (es) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
| WO2008150364A1 (en) * | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| AU2008276055B2 (en) | 2007-07-17 | 2013-01-31 | Bristol-Myers Squibb Company | Pyridone GPR119 G protein-coupled receptor agonists |
| KR101204213B1 (ko) | 2007-12-21 | 2012-11-26 | 에프. 호프만-라 로슈 아게 | 오렉신 수용체 길항제로서의 헤테로아릴 유도체 |
| NZ588080A (en) * | 2008-02-21 | 2012-04-27 | Actelion Pharmaceuticals Ltd | 2-Aza-bicyclo[2.2.1]heptane derivatives |
| EP2318367B1 (en) | 2008-04-30 | 2013-03-20 | Actelion Pharmaceuticals Ltd. | Piperidine and pyrrolidine compounds |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| EP2349269A4 (en) | 2008-10-21 | 2012-04-25 | Merck Sharp & Dohme | 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS |
| JP2012506378A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，３−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト |
| AU2009324239A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
| CN102459229A (zh) | 2009-04-24 | 2012-05-16 | 葛兰素集团有限公司 | 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷 |
| WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| MX2012004753A (es) | 2009-10-23 | 2012-09-07 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina. |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| WO2011053688A1 (en) | 2009-10-29 | 2011-05-05 | Schering Corporation | Bridged bicyclic piperidine derivatives and methods of use thereof |
| WO2011066137A1 (en) | 2009-11-24 | 2011-06-03 | Schering Corporation | Substituted biaryl derivatives and methods of use thereof |
| JP2013513664A (ja) | 2009-12-14 | 2013-04-22 | インスパイアー ファーマシューティカルズ，インコーポレイティド | 架橋二環式ｒｈｏキナーゼ阻害化合物、組成および使用 |
| WO2011087812A1 (en) | 2009-12-21 | 2011-07-21 | Vanderbilt University | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| US20130096141A1 (en) | 2010-06-18 | 2013-04-18 | Bernard R. Neustadt | Bicyclic heterocycle derivatives and methods of use thereof |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| EP2911675A4 (en) | 2012-10-23 | 2016-06-01 | Merck Sharp & Dohme | 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS |
| AU2013347538B2 (en) | 2012-11-16 | 2017-04-27 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| JP6532474B2 (ja) | 2014-02-06 | 2019-06-19 | アッヴィ・インコーポレイテッド | ６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用 |
| WO2016040789A1 (en) | 2014-09-11 | 2016-03-17 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
-
2014
- 2014-03-11 TW TW103108293A patent/TWI621618B/zh active
- 2014-03-12 KR KR1020157028720A patent/KR102209424B1/ko not_active Expired - Fee Related
- 2014-03-12 EA EA201591703A patent/EA029276B1/ru unknown
- 2014-03-12 AU AU2014248680A patent/AU2014248680B2/en active Active
- 2014-03-12 HU HUE19193122A patent/HUE063608T2/hu unknown
- 2014-03-12 CN CN201810842686.7A patent/CN108864093A/zh active Pending
- 2014-03-12 EP EP23176328.5A patent/EP4272824A3/en not_active Withdrawn
- 2014-03-12 JP JP2016501487A patent/JP6275815B2/ja active Active
- 2014-03-12 RS RSP20191419 patent/RS59466B1/sr unknown
- 2014-03-12 HR HRP20230633TT patent/HRP20230633T1/hr unknown
- 2014-03-12 EP EP14717576.4A patent/EP2970314B1/en active Active
- 2014-03-12 PT PT172064917T patent/PT3363438T/pt unknown
- 2014-03-12 EP EP19193122.9A patent/EP3622956B9/en active Active
- 2014-03-12 MX MX2015011815A patent/MX361529B/es active IP Right Grant
- 2014-03-12 HR HRP20180303TT patent/HRP20180303T1/hr unknown
- 2014-03-12 SM SM20180056T patent/SMT201800056T1/it unknown
- 2014-03-12 RS RS20180158A patent/RS56875B1/sr unknown
- 2014-03-12 ME MEP-2018-46A patent/ME03011B/me unknown
- 2014-03-12 PT PT147175764T patent/PT2970314T/pt unknown
- 2014-03-12 SI SI201431351T patent/SI3363438T1/sl unknown
- 2014-03-12 CN CN201910948604.1A patent/CN110669052B/zh active Active
- 2014-03-12 SG SG11201507415QA patent/SG11201507415QA/en unknown
- 2014-03-12 MY MYPI2015703021A patent/MY183725A/en unknown
- 2014-03-12 DK DK14717576.4T patent/DK2970314T3/en active
- 2014-03-12 EP EP17206491.7A patent/EP3363438B1/en active Active
- 2014-03-12 CR CR20210523A patent/CR20210523A/es unknown
- 2014-03-12 PE PE2015001954A patent/PE20151599A1/es active IP Right Grant
- 2014-03-12 LT LTEP14717576.4T patent/LT2970314T/lt unknown
- 2014-03-12 CN CN201480027437.2A patent/CN105308048B/zh active Active
- 2014-03-12 SM SM20230223T patent/SMT202300223T1/it unknown
- 2014-03-12 PL PL14717576T patent/PL2970314T3/pl unknown
- 2014-03-12 CA CA2904618A patent/CA2904618C/en active Active
- 2014-03-12 SM SM20190655T patent/SMT201900655T1/it unknown
- 2014-03-12 LT LT17206491T patent/LT3363438T/lt unknown
- 2014-03-12 UA UAA201509932A patent/UA118669C2/uk unknown
- 2014-03-12 DK DK17206491T patent/DK3363438T3/da active
- 2014-03-12 HU HUE14717576A patent/HUE036193T2/hu unknown
- 2014-03-12 HU HUE17206491A patent/HUE047592T2/hu unknown
- 2014-03-12 US US14/206,722 patent/US8969352B2/en active Active
- 2014-03-12 MX MX2018015165A patent/MX368466B/es unknown
- 2014-03-12 ES ES19193122T patent/ES2950032T3/es active Active
- 2014-03-12 SI SI201430542T patent/SI2970314T1/en unknown
- 2014-03-12 US US14/774,555 patent/US9611277B2/en active Active
- 2014-03-12 RS RS20230703A patent/RS64551B9/sr unknown
- 2014-03-12 JO JOP/2014/0092A patent/JOP20140092B1/ar active
- 2014-03-12 ES ES14717576.4T patent/ES2659397T3/es active Active
- 2014-03-12 ES ES17206491T patent/ES2760564T3/es active Active
- 2014-03-12 BR BR112015022294-3A patent/BR112015022294B1/pt active IP Right Grant
- 2014-03-12 PL PL17206491T patent/PL3363438T3/pl unknown
- 2014-03-12 ME MEP-2019-314A patent/ME03572B/me unknown
- 2014-03-12 WO PCT/US2014/024293 patent/WO2014165070A1/en not_active Ceased
- 2014-03-12 PL PL19193122.9T patent/PL3622956T3/pl unknown
- 2014-03-13 UY UY0001035409A patent/UY35409A/es not_active Application Discontinuation
- 2014-03-13 AR ARP140100967A patent/AR095423A1/es active IP Right Grant
- 2014-11-19 NO NO14808529A patent/NO3107630T3/no unknown
-
2015
- 2015-01-26 US US14/605,387 patent/US9447117B2/en active Active
- 2015-08-10 IL IL240466A patent/IL240466B/en active IP Right Grant
- 2015-08-24 CR CR20150433A patent/CR20150433A/es unknown
- 2015-09-02 PH PH12015501929A patent/PH12015501929B1/en unknown
- 2015-09-10 NI NI201500130A patent/NI201500130A/es unknown
- 2015-09-11 CL CL2015002609A patent/CL2015002609A1/es unknown
- 2015-10-12 ZA ZA2015/07562A patent/ZA201507562B/en unknown
-
2016
- 2016-08-26 US US15/248,945 patent/US9845333B2/en active Active
-
2017
- 2017-04-04 US US15/478,888 patent/US10183953B2/en active Active
-
2018
- 2018-03-09 CY CY20181100284T patent/CY1120024T1/el unknown
- 2018-07-03 AU AU2018204835A patent/AU2018204835B2/en active Active
-
2019
- 2019-02-03 IL IL264606A patent/IL264606A/en unknown
- 2019-11-08 HR HRP20192032TT patent/HRP20192032T1/hr unknown
- 2019-12-02 CY CY20191101261T patent/CY1122392T1/el unknown
-
2023
- 2023-07-25 CY CY20231100361T patent/CY1126106T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501929A1 (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| PH12015502030A1 (en) | Substituted 7-azabicycles and their use as orexin receptor modulators | |
| NZ732810A (en) | Picolinamides and other compounds | |
| PH12015502047A1 (en) | Novel pyrimidine and pyridine compounds and their usage | |
| PH12016501007A1 (en) | Substituted benzamides and methods of use thereof | |
| MX351581B (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| JO3509B1 (ar) | معدلات p2x7 | |
| MX2015015786A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas. | |
| MY153042A (en) | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | |
| MX2018005133A (es) | Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos. | |
| MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
| MX366678B (es) | Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona. | |
| MX370389B (es) | Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona. | |
| SA519400868B1 (ar) | معدلات عطرية غير متجانسة لأشعة جاما لمستقبل يتيم ذي علاقة بريتينويد | |
| MX368759B (es) | Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona. | |
| UA107357C2 (ru) | Производные (6-оксо-1,6-дигидропиримидин-2-ил)амида, их получение и их фармацевтическое применение в качестве ингибиторов фосфорилирования акт (ркв) |